CARBAFORM

Anticancer antibodies primarily act through a mechanism called antibody-dependent cell-mediated cytotoxicity (ADCC). Decreasing antibody fucosylation enables up to 50-fold improvement in ADCC activity - with the added benefit of allowing targeting of low-density antigens. 

​

At Carbaform Biosciences we have developed a convenient feed additive that allows producing antibodies with tunable levels of fucosylation. Simple to use with existing cell lines without affecting cell growth or antibody titer.

​

Carbaform is seeking to partner its technology to help accelerate the delivery of life-saving new therapeutics and biobetters. Click below to find out more about our technology and tools. 

​